Literature DB >> 21800057

Treatment options for sleep dysfunction in Parkinson's disease.

Mary Ann Thenganatt1, Steven J Frucht.   

Abstract

OPINION STATEMENT: Sleep disturbance is an important feature of Parkinson's disease (PD) that deserves clinical attention. Various disorders need to be considered and treatment should be customized to the patient's specific symptoms and lifestyle. Evaluation of a PD patient complaining of difficulty sleeping begins with a detailed history from the patient and bed partner about the specific problem the patient is experiencing. It is important to inquire about difficulties with sleep onset, frequent awakenings, increased movements during sleep, acting out dreams, uncomfortable motor symptoms, disordered breathing, and nocturia. Current medications should be reviewed to determine whether the recent addition of a drug or a change in dose may be contributing to sleep difficulties, and one should ask about daytime sleepiness, frequent daytime naps, and sleep hygiene in the evening that can contribute to problems sleeping at night. The goal of therapy is to restore quality nighttime sleep without excessive daytime sedation and to improve the patient's daily mental and physical function and overall quality of life.

Entities:  

Year:  2011        PMID: 21800057     DOI: 10.1007/s11940-011-0139-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  76 in total

1.  Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.

Authors:  Dan A Mendonça; Krishe Menezes; Mandar S Jog
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

2.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

3.  Sleep induced by stimulation in the human pedunculopontine nucleus area.

Authors:  Isabelle Arnulf; Muriel Ferraye; Valérie Fraix; Alim Louis Benabid; Stephan Chabardès; Laurent Goetz; Pierre Pollak; Bettina Debû
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

4.  Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Authors:  Charles H Adler; John N Caviness; Joseph G Hentz; Marlene Lind; Judy Tiede
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

5.  Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study).

Authors:  Wolfgang H Oertel; Karin Stiasny-Kolster; Bettina Bergtholdt; Yngve Hallström; Jaan Albo; Lena Leissner; Thomas Schindler; Juergen Koester; Juergen Reess
Journal:  Mov Disord       Date:  2007-01-15       Impact factor: 10.338

6.  Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease.

Authors:  Juan Carlos Gómez-Esteban; Beatriz Tijero; Johanne Somme; Roberto Ciordia; Koldo Berganzo; Idoia Rouco; Jose Luis Bustos; Maria Antonia Valle; Elena Lezcano; Juan J Zarranz
Journal:  J Neurol       Date:  2010-10-19       Impact factor: 4.849

7.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

8.  Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.

Authors:  Charles A Czeisler; James K Walsh; Keith A Wesnes; Sanjay Arora; Thomas Roth
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 9.  Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains.

Authors:  Stefani Alessandro; Roberto Ceravolo; Livia Brusa; Mariangela Pierantozzi; Alberto Costa; Salvatore Galati; Fabio Placidi; Andrea Romigi; Cesare Iani; Francesco Marzetti; Antonella Peppe
Journal:  J Neurol Sci       Date:  2009-09-17       Impact factor: 3.181

10.  Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.

Authors:  Ilonka Eisensehr; Bruce L Ehrenberg; Silvia Rogge Solti; Soheyl Noachtar
Journal:  J Neurol       Date:  2004-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.